Silo Pharma Inc (SILO) - Net Assets
Based on the latest financial reports, Silo Pharma Inc (SILO) has net assets worth $4.89 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($5.95 Million) and total liabilities ($1.07 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check SILO PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $4.89 Million |
| % of Total Assets | 82.09% |
| Annual Growth Rate | 32.27% |
| 5-Year Change | -30.42% |
| 10-Year Change | 644.88% |
| Growth Volatility | 181.65 |
Silo Pharma Inc - Net Assets Trend (2010–2025)
This chart illustrates how Silo Pharma Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see SILO market cap.
Annual Net Assets for Silo Pharma Inc (2010–2025)
The table below shows the annual net assets of Silo Pharma Inc from 2010 to 2025. Also explore Silo Pharma Inc equity growth rate to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $6.31 Million | +25.25% |
| 2024-12-31 | $5.03 Million | -18.50% |
| 2023-12-31 | $6.18 Million | -40.27% |
| 2022-12-31 | $10.34 Million | +14.11% |
| 2021-12-31 | $9.06 Million | +607.61% |
| 2020-12-31 | $1.28 Million | +5694.51% |
| 2019-12-31 | $-22.89K | -105.62% |
| 2018-12-31 | $407.44K | -66.13% |
| 2017-12-31 | $1.20 Million | +42.12% |
| 2016-12-31 | $846.51K | -56.80% |
| 2015-12-31 | $1.96 Million | -17.29% |
| 2014-12-31 | $2.37 Million | +32.44% |
| 2013-12-31 | $1.79 Million | +4442.06% |
| 2012-12-31 | $-41.19K | -2256.64% |
| 2011-12-31 | $-1.75K | -101.84% |
| 2010-12-31 | $94.96K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Silo Pharma Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1841388400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.33K | 0.02% |
| Other Comprehensive Income | $5.83K | 0.09% |
| Other Components | $25.79 Million | 409.02% |
| Total Equity | $6.31 Million | 100.00% |
Silo Pharma Inc Competitors by Market Cap
The table below lists competitors of Silo Pharma Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Cerebra Integrated Technologies Limited
NSE:CEREBRAINT
|
$3.40 Million |
|
BioNexus Gene Lab Corp Common stock
NASDAQ:BGLC
|
$3.40 Million |
|
Madhav Marbles and Granites Limited
NSE:MADHAV
|
$3.40 Million |
|
Crown Capital Partners Inc
TO:CRWN
|
$3.41 Million |
|
Vaxtex Cotfab Limited
NSE:VCL
|
$3.40 Million |
|
Australian Silica Quartz Group Ltd
AU:ASQ
|
$3.39 Million |
|
NIOX Group PLC
LSE:NIOX
|
$3.39 Million |
|
Mustang Bio Inc
NASDAQ:MBIO
|
$3.39 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Silo Pharma Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 5,034,265 to 6,305,441, a change of 1,271,176 (25.3%).
- Net loss of 4,227,698 reduced equity.
- New share issuances of 3,725,236 increased equity.
- Other comprehensive income increased equity by 3,409.
- Other factors increased equity by 1,770,229.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-4.23 Million | -67.05% |
| Share Issuances | $3.73 Million | +59.08% |
| Other Comprehensive Income | $3.41K | +0.05% |
| Other Changes | $1.77 Million | +28.07% |
| Total Change | $- | 25.25% |
Book Value vs Market Value Analysis
This analysis compares Silo Pharma Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.17x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | $-0.04 | $1.94 | x |
| 2012-12-31 | $-1.01 | $1.94 | x |
| 2013-12-31 | $41.36 | $1.94 | x |
| 2014-12-31 | $37.08 | $1.94 | x |
| 2015-12-31 | $29.05 | $1.94 | x |
| 2016-12-31 | $12.65 | $1.94 | x |
| 2017-12-31 | $17.32 | $1.94 | x |
| 2018-12-31 | $6.22 | $1.94 | x |
| 2019-12-31 | $-0.41 | $1.94 | x |
| 2020-12-31 | $14.56 | $1.94 | x |
| 2021-12-31 | $4.72 | $1.94 | x |
| 2022-12-31 | $4.53 | $1.94 | x |
| 2023-12-31 | $2.01 | $1.94 | x |
| 2024-12-31 | $20.52 | $1.94 | x |
| 2025-12-31 | $11.28 | $1.94 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Silo Pharma Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -67.05%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -5863.50%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.21x
- Recent ROE (-67.05%) is below the historical average (-54.72%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-49.63K |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-35.33K |
| 2013 | 1.84% | 31.19% | 0.05x | 1.23x | $-145.96K |
| 2014 | -15.90% | 0.00% | -0.04x | 1.17x | $-613.45K |
| 2015 | -20.90% | 0.00% | -0.06x | 1.25x | $-605.45K |
| 2016 | -131.48% | 0.00% | -0.52x | 1.54x | $-1.20 Million |
| 2017 | 29.64% | 42.07% | 0.52x | 1.36x | $236.23K |
| 2018 | -237.94% | 0.00% | 0.00x | 2.10x | $-1.01 Million |
| 2019 | 0.00% | -2497.71% | 0.08x | 0.00x | $-1.01 Million |
| 2020 | -237.18% | -7422.52% | 0.03x | 1.11x | $-3.17 Million |
| 2021 | 43.08% | 5477.86% | 0.01x | 1.16x | $3.00 Million |
| 2022 | -37.80% | -5420.86% | 0.01x | 1.13x | $-4.94 Million |
| 2023 | -59.91% | -5132.57% | 0.01x | 1.25x | $-4.32 Million |
| 2024 | -87.26% | -6092.59% | 0.01x | 1.47x | $-4.90 Million |
| 2025 | -67.05% | -5863.50% | 0.01x | 1.21x | $-4.86 Million |
Industry Comparison
This section compares Silo Pharma Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $161,895,707
- Average return on equity (ROE) among peers: -42.53%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Silo Pharma Inc (SILO) | $4.89 Million | 0.00% | 0.22x | $3.40 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $109.30 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $170.10 Million | -16.06% | 0.05x | $310.51 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-12.35 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.35 Billion |
| Arbutus Biopharma Corp (ABUS) | $38.29 Million | -30.60% | 0.11x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $2.46 Million | -172.46% | 1.68x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.66 Million | -45.66% | 0.56x | $9.31 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $199.76 Million | -82.32% | 0.11x | $4.61 Billion |
About Silo Pharma Inc
Silo Pharma, Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company's… Read more